GE Global Research in Niskayuna, NY, has launched a study with Memorial Sloan-Kettering Cancer Center in New York City to explore the early stages of colon cancer.
The goal is to yield new insights that improve treatment selection and outcomes for cancer patients.
As part of the study, GE and Memorial Sloan-Kettering will collaborate to evaluate biomarkers for their prognostic value to segregate high- from low-risk early-stage colon cancers. Scientists and investigators from GE and Memorial Sloan-Kettering will work together to identify cancer cases, acquire and process cancer tissues, and collect treatment outcome information, then biochemically and statistically analyze the molecular profiles for the cancer tissues, and relate the molecular profiles to treatment outcomes.
Related Reading
GE offers meaningful use IT software, July 20, 2010
GE Healthcare grows in Q2, July 16, 2010
GE relaunches Optison ultrasound contrast, July 12, 2010
iCRco, GE sign distribution deal, June 24, 2010
GE reveals work on new MBI system, June 23, 2010
Copyright © 2010 AuntMinnie.com
%20sep%2023.nRERZIE5K0.jpg?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20sep%2023.nRERZIE5K0.jpg?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
